Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Rises By 1,984.9%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 702,600 shares, a growth of 1,984.9% from the October 15th total of 33,700 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 34.8% of the shares of the company are short sold.

Shuttle Pharmaceuticals Stock Down 3.6 %

Shares of NASDAQ:SHPH traded down $0.04 on Thursday, hitting $1.07. The stock had a trading volume of 103,182 shares, compared to its average volume of 470,504. The company has a 50 day moving average of $1.37. Shuttle Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $4.95. The company has a market cap of $3.16 million, a P/E ratio of -0.32 and a beta of -1.32.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its earnings results on Tuesday, September 3rd. The company reported ($0.96) EPS for the quarter.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .